Immunology and Microbiology
Adoptive Immunity
11%
Blocking Antibody
6%
Blood Plasma
11%
Booster Dose
11%
Breakthrough Infection
28%
Campylobacter Concisus
11%
CD4
6%
Chemoluminescence
11%
Comorbidity
22%
COVID-19
41%
Factor H
5%
Hepatitis A Virus
5%
Human Immunodeficiency Virus
22%
Human Respiratory Syncytial Virus
11%
Hybrid Immunity
11%
Immune Response
17%
Immunogenicity
18%
Innate Immune System
5%
Leukocyte Activation
11%
Lower Respiratory Tract
5%
Meningococcal Vaccine
11%
Monospecific Antibody
34%
Mortality Rate
6%
Neutralizing Antibody
11%
Neutrophil
5%
Neutrophil Granulocyte
5%
Normal Human
17%
Omicron Coronavirus Variant
35%
Opsonin
8%
Pneumococcal Vaccine
11%
Polymerase Chain Reaction
7%
Protein Binding
5%
Receptor Blocking
5%
Respiratory Burst
8%
Serotype
22%
Severe Acute Respiratory Syndrome Coronavirus 2
71%
Spike
38%
Tetanus Vaccine
11%
Titer
24%
Toxoplasmosis
11%
Vaccination Policy
42%
Vaccine Efficacy
100%
Virus Vaccine
5%
Medicine and Dentistry
Adolescent
11%
Antiretroviral Therapy
12%
Antivirus Agent
5%
Blocking Antibody
9%
Booster Dose
11%
Camostat Mesilate
11%
Cellular Immunity
12%
Cohort Analysis
36%
Complement Factor H
7%
COVID-19
41%
COVID-19 Vaccination
7%
COVID-19 Vaccine
34%
Cryptococcal Meningitis
11%
Disease
21%
Drug Use
9%
Hepatitis A Virus
7%
Highly Active Antiretroviral Therapy
11%
Human Immunodeficiency Virus
27%
Human Immunodeficiency Virus 1
11%
Hyperimmune Globulin
11%
Immune Response
19%
Immunogenicity
7%
Immunoglobulin
11%
Infection
36%
Infusion
6%
Intention-to-Treat Analysis
8%
Interferon Gamma Release Assay
14%
Latent Tuberculosis
12%
Meningococcus Vaccine
11%
Mortality Rate
6%
Neutralizing Antibody
14%
Odds Ratio
6%
Omicron Coronavirus Variant
13%
Placebo
22%
Prophylaxis
5%
Prospective Cohort Study
11%
Protein Binding
7%
Randomized Controlled Trial
11%
Receptor Blocking
11%
Serotype
11%
Severe Acute Respiratory Syndrome Coronavirus 2
57%
Sputum
8%
Tetanus Toxoid
11%
Tuberculosis
11%
Virus Vaccine
7%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
11%
All Cause Mortality
5%
Antibodies
8%
Blocking Antibody
9%
Camostat
5%
Camostat Mesilate
22%
Cerebral Toxoplasmosis
11%
Cohort Study
24%
Comorbidity
11%
Coronavirinae
16%
COVID-19 Vaccine
22%
Disease
29%
HIV
22%
Human Respiratory Syncytial Virus
11%
Hyperimmune Globulin
11%
Immunoglobulin
11%
Infection
21%
Latent Tuberculosis
11%
Molnupiravir
11%
Monoclonal Antibody
11%
Mortality Rate
8%
Neutralizing Antibody
13%
Placebo
63%
Prospective Cohort Study
11%
Randomized Controlled Trial
22%
Receptor
11%
Remdesivir
13%
Respiratory Tract
9%
SARS Coronavirus
40%
Serine Proteinase
11%
Toxoplasmosis
11%
Tuberculosis
11%
Vaccination Policy
27%
Vaccine
9%
